Cara Therapeutics Inc logo

Cara Therapeutics Inc

1
NAS:CARA (USA)  
$ 0.80 -0.106 (-11.69%) 11:08 PM EST
At Loss
P/B:
0.58
Market Cap:
$ 49.42M
Enterprise V:
$ -21.81M
Volume:
1.82M
Avg Vol (2M):
768.28K
Also Trade In:
Volume:
1.82M
At Loss
Avg Vol (2M):
768.28K

Business Description

Description
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Name Current Vs Industry Vs History
Cash-To-Debt 10.74
Equity-to-Asset 0.74
Debt-to-Equity 0.09
Debt-to-EBITDA -0.06
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -9.26
Distress
Grey
Safe
Beneish M-Score -3.91
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 64.96
9-Day RSI 65.94
14-Day RSI 62.18
6-1 Month Momentum % -79.26
12-1 Month Momentum % -94.25

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.4
Quick Ratio 4.25
Cash Ratio 3.43
Days Inventory 136.77
Days Sales Outstanding 111.52
Days Payable 468.07

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.8
Shareholder Yield % 0.23

Financials (Next Earnings Date:2024-03-04)

CARA's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CARA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Cara Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 21.225
EPS (TTM) ($) -2.15
Beta 0.44
Volatility % 56.01
14-Day RSI 62.18
14-Day ATR ($) 0.095608
20-Day SMA ($) 0.61926
12-1 Month Momentum % -94.25
52-Week Range ($) 0.5 - 10.39
Shares Outstanding (Mil) 54.48

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cara Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Cara Therapeutics Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Cara Therapeutics Inc Frequently Asked Questions

What is Cara Therapeutics Inc(CARA)'s stock price today?
The current price of CARA is $0.80. The 52 week high of CARA is $10.39 and 52 week low is $0.50.
When is next earnings date of Cara Therapeutics Inc(CARA)?
The next earnings date of Cara Therapeutics Inc(CARA) is 2024-03-04.
Does Cara Therapeutics Inc(CARA) pay dividends? If so, how much?
Cara Therapeutics Inc(CARA) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1